228.49
-4.72 (-2.02%)
| Previous Close | 233.21 |
| Open | 231.43 |
| Volume | 1,224,341 |
| Avg. Volume (3M) | 1,419,793 |
| Market Cap | 37,559,611,392 |
| Price / Earnings (TTM) | 44.54 |
| Price / Earnings (Forward) | 27.55 |
| Price / Sales | 12.94 |
| Price / Book | 5.55 |
| 52 Weeks Range | |
| Earnings Date | 4 Mar 2026 |
| Profit Margin | 27.34% |
| Operating Margin (TTM) | 30.79% |
| Diluted EPS (TTM) | 4.70 |
| Quarterly Revenue Growth (YOY) | 16.70% |
| Quarterly Earnings Growth (YOY) | 41.20% |
| Total Debt/Equity (MRQ) | 1.24% |
| Current Ratio (MRQ) | 4.61 |
| Operating Cash Flow (TTM) | 1.20 B |
| Levered Free Cash Flow (TTM) | 1.05 B |
| Return on Assets (TTM) | 6.90% |
| Return on Equity (TTM) | 14.06% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Health Information Services (US) | Bearish | Bearish |
| Health Information Services (Global) | Bearish | Bearish | |
| Stock | Veeva Systems Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | -3.0 |
| Price Volatility | -1.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.20 |
|
Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company’s best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company. |
|
| Sector | Healthcare |
| Industry | Health Information Services |
| Investment Style | Mid Growth |
| % Held by Insiders | 8.55% |
| % Held by Institutions | 86.32% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Linonia Partnership Lp | 30 Sep 2025 | 2,970,254 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 355.00 (Needham, 55.37%) | Buy |
| Median | 319.00 (39.61%) | |
| Low | 280.00 (UBS, 22.54%) | Hold |
| 280.00 (Canaccord Genuity, 22.54%) | Hold | |
| Average | 314.56 (37.67%) | |
| Total | 6 Buy, 3 Hold | |
| Avg. Price @ Call | 247.97 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wells Fargo | 25 Nov 2025 | 333.00 (45.74%) | Buy | 239.95 |
| Citigroup | 24 Nov 2025 | 319.00 (39.61%) | Buy | 235.74 |
| BTIG | 21 Nov 2025 | 340.00 (48.80%) | Buy | 244.06 |
| 17 Oct 2025 | 340.00 (48.80%) | Buy | 283.73 | |
| Baird | 21 Nov 2025 | 319.00 (39.61%) | Buy | 244.06 |
| Barclays | 21 Nov 2025 | 305.00 (33.49%) | Buy | 244.06 |
| Canaccord Genuity | 21 Nov 2025 | 280.00 (22.54%) | Hold | 244.06 |
| Needham | 21 Nov 2025 | 355.00 (55.37%) | Buy | 244.06 |
| 17 Oct 2025 | 355.00 (55.37%) | Buy | 283.73 | |
| UBS | 21 Nov 2025 | 280.00 (22.54%) | Hold | 244.06 |
| BMO Capital | 13 Nov 2025 | 300.00 (31.30%) | Hold | 291.70 |
| Show more | ||||
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |